ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Astellas Pharma and Applied Biology side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Astellas PharmaApplied Biology
studies on the registry98325
open to participants now385
phase 3 studies under way133
reach primary completion within a year143
programswith a study of their own in two years205

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstellas PharmaApplied Biology
Phase 1

Astellas Pharma: 2 of its 20 programs at phase 1

  1. ASP2020phase 1
  2. Pan-KRAS Degrader ASP5834phase 1
10%
00%
Phase 245%

Applied Biology: 3 of its 5 programs at phase 2

  1. DA-020phase 2
  2. CS-002phase 2
  3. hyperforinphase 2
60%
Phase 3

Astellas Pharma: 4 of its 20 programs at phase 3

  1. fezolinetantphase 3
  2. setidegrasibphase 3
  3. emaretamigphase 3
  4. gilteritinibphase 3
20%

Applied Biology: 2 of its 5 programs at phase 3

  1. CS-001phase 3
  2. DA-007phase 3
40%
Approved, new studies

Astellas Pharma: 5 of its 20 programs at approved, new studies

  1. zolbetuximabapproved, new study
  2. enfortumab vedotinapproved, new study
  3. enzalutamideapproved, new study
  4. avacincaptad pegolapproved, new study
  5. Sirolimusapproved, new study
25%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Astellas Pharma9 readouts · 2 phase 3·

Astellas Pharma, Dec ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Cphase 2 · Dec 30 · NCT06792435
  2. enfortumab vedotinapproved, new study · Dec 31 · NCT06862219
  3. zolbetuximabapproved, new study · Dec 31 · NCT06396091
···

Astellas Pharma, Apr ’27: 2 programs whose next study reaches primary completion

  1. enzalutamideapproved, new study · Apr 30 · NCT07783282
  2. fezolinetantphase 3 · Apr 30 · NCT07783282
·

Astellas Pharma, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. avacincaptad pegolapproved, new study · Jun 30 · NCT06970665
···

Astellas Pharma, Oct ’27: 3 programs whose next study reaches primary completion

  1. Methylprednisolonephase 2 · Oct 31 · NCT07052929
  2. Prednisolonephase 2 · Oct 31 · NCT07052929
  3. Sirolimusapproved, new study · Oct 31 · NCT07052929
Applied Biology3 readouts · 0 phase 3···

Applied Biology, Feb ’27: 2 programs whose next study reaches primary completion

  1. DA-020phase 2 · Feb 5 · NCT07397325
  2. hyperforinphase 2 · Feb 5 · NCT07397325
·······

Applied Biology, Oct ’27: 1 program whose next study reaches primary completion

  1. CS-002phase 2 · Oct 15 · NCT07166354
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Astellas Pharma

New programs 1

  • ASP2957phase 2 · first study · Oct 9 · Myopathies, Structural, Congenital

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Applied Biology

New programs 0

None

Reached a new phase 0

None

Study stopped 1

  • DA-020early phase 1 · withdrawn Nov 2“Change of protocol moved to new study” · NCT07402330

Primary completion later 3

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Astellas Pharma 12 of 20 · Applied Biology 0 of 5 programs (11 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.